Alkem Laboratories Ltd.

was Iounded in the year 1974 with a dream to reach out quality Health Iood to people
and improve quality oI liIe with exceptional products and services.

Nearing its Iourth decade oI successIul existence, Alkem Lab`s dreams have transpired to elevate the lives oI
millions oI people worldwide. Propelled with dedication and the passion to achieve and deliver, Alkem Lab`s
has journeyed to be known the world over as a premier Health Iood institution in generic and branded
Iormulations.


Alkem Lab`s has recently added a new milestone to its successIul journey so Iar by setting up one oI the
world`s largest Sucralose producing unit in India. AIter signiIicant research and identiIying the huge business
potential, Alkem Lab`s has initiated its presence in the health Iood market. The product range in health Ioods
would largely be based on wide applications oI FOS (Fructo Oligosaccharide), a natural sweetener with
prebiotic properties and Sucralose, a natural, sugar-Iree low calorie sweetener.

Headquartered in Mumbai, Alkem Lab`s stands proud as the 7th largest pharmaceutical and Health Iood
Company in India, taking strides towards the lead position in India and worldwide. With robust sales revenues
exceeding US$400 million and a healthy growth oI over 20 annually, Lab`s success accelerates even in the
increasingly competitive environment not just in India but also internationally.

H!CHL!CHTS


India

- Leader in Anti-inIective segment and ranked No. 1 in Cephalosporins market
- Recognized leader in Gastroenterology, Pain Management and Anti-osteoporosis
market
- 2 brands amongst the top 25 brands and 11 brands amongst the top 300 brands
- 28 brands with sales exceeding US$ 2 million
- One oI the best brand building talents, marketing expertise and sales network
- 7 world class in-house manuIacturing Iacilities spread across the country accredited
with international regulatory approvals







International

- Presence in more than 40 countries including regulated markets oI the EU, CIS
countries and South East Asia
- 15 ANDAs and approvals Ior 6 products in the US markets with several others lined
up Ior USFDA approval
- Several products in the pipeline nearing approval Ior US, European and Asian
markets






Our Vision

To achieve value driven leadership through...
- Quality that`s inIinite

- Service that`s caring
- Hardwork that`s enduring

In India, we are collaborating our combined eIIorts to regain and surge to the coveted
top 5 pharmaceutical companies by 2012. We wish to achieve this milestone through
organic growth and inorganically through international partnerships and strategic
alliances that would enhance our reach globally.




Our Mission

To be the benchmark in Health Iood through...
- Integrity that`s inspiring
- Clarity that`s assuring
- Consistency that`s time tested






Our Values

At Alkem Lab`s, we believe that Health Iood is not bound by geographical boundaries
and the world is not Iar Irom reach. We stretch our imagination and resources to deliver
the best in Health Iood to places Iar and near, making the globe our playground.

Our People First` policy ensures that we IulIill and surpass the ever growing customer
expectations in every way possible. AIter all, quality Health Iood plays a integral role
towards leading a healthy and happy liIe.

At Alkem Lab`s, 3 vital elements support our spirit to succeed all the time:
Knowledge : We encourage our team to study, understand and enhance their
knowledge on any subject that they are brieIed in their career

Passion : The constant thrust oI enthusiasm at Alkem Lab`s propels our Iorce to
complete a given task and at the same time encourages their peers to contribute
accordingly

Accountability : While knowledge and passion push us into uncharted Health Iood
spaces, accountability ensures we dedicate our attention to seeing things Irom ideation
through implementation






Proudly Indian, Alkem Lab`s Laboratories Ltd., Iounded in 1974, is a US$ 400 million pharmaceutical
transnational serving the interests oI the medical community in India and across 40 countries worldwide since
almost 4 decades. Alkem Lab`s Labs has evolved to the prominent Iore oI the Indian pharmaceutical industry
and is currently ranked the 7th largest pharmaceutical company in India leading the Iormulations segment
covering both acute and chronic therapeutics. Empowering the hands that treat and care, combined with an
experience oI disease management, oIIering diverse therapeutic segments, Alkem Lab`s Iorte lies in its brand
building skills, marketing expertise and sales network which reIlects in our 11 Ilagship brands that today rank
amongst the top 300 brands in India.

Alkem Lab`s 7 in-house world class manuIacturing Iacilities are approved by the most stringent and prestigious

international quality regulatory authorities including US - FDA, UK - MHRA, MCC - South AIrica and TGA -
Australia. Alkem Lab`s quality products reach out to millions oI Indians and people across more than 40
countries including regulated markets oI US, EU, CIS countries and South East Asia.

istribution/Logistics:-
Since inception, Alkem Lab`s has put in immense eIIorts and planning to build a robust distribution network.
Today, we are proud to have one oI the largest logistic and distribution network set-up in India covering the
entire length and breadth oI the country. Alkem Lab`s reaches quality Health Iood to places Iar and near in
India and worldwide.

We distribute our products through 20 depots, 4 C&F agents and a strong network oI 5500 stockists. In India,
we cover almost 2,50,000 retail pharmacies and the number keeps growing. The Alkem Lab`s quality is
maintained at every level oI distribution Irom manuIacture to the end customer.

Indian Formulations

Alkem Lab`s, over a span oI nearly Iour decades has developed a strong reputation oI its strengths in marketing
and sales which reIlect the sturdy eIIorts and Iocus on brand building.

11 oI Alkem Lab`s brands are listed in the top 300 pharmaceutical brands in India, as per June 2011 IMS.
Alkem Lab`s is rated No. 1 in Cephalosporin Iormulations and No. 2 in the overall anti-bacterial segment.
Alkem Lab`s has touched most oI the therapy segments including Gastroenterology, Orthopaedics, Oncology,
Neuropsychiatry, Cardiovascular and Gynaecology to mention a Iew, and is considered as Iorerunners in some
segments.

SBUs (Strategic Business Units)
At Alkem Lab`s, our domestic business is modelled through strong and established therapy Iocussed Strategic
Business Units (SBUs).

Our SBUs Iocus on respective therapies as Iollows:


Main (Alkem I/II)

Ulticare

Bergen

Alkem
Pharma
Pentacare Neuroscience

Anti-inIective
Pain Management &
Gastro Division

Anti-
inIective
&
Respiratory
Division

Anti-inIective
Bone Health
Division

Extra Urban
Division


Neurology
Advanced
Neurology

















Bergen Zurieve

erma Care

Mediva

Cytomed

Aliva Futura

Gynecology and
InIertility
Dermatology


Cardiology &
Diabetology
Oncology
Division
Generic Division



While the Main SBU, Ulticare and Bergen are the torchbearers oI Alkem Lab`s successIul run, the newer
speciality SBUs, Pentacare (Neurology), Neurosciences (Neuropsychiatry), Mediva (Cardio-Diabeto),
Cytomed (Oncology) and Dermacare (Dermatology) are gaining momentum and are enhancing their market
share in the chronic therapy segment with a wide range oI products in their respective categories.

Alkem Lab`s generic business shares a substantial share oI the market with its two SBUs Aliva and Futura
Iocused exclusively on generics.

Alkem Lab`s Pharma is Alkem Lab`s endeavour to venture into the potential extra-urban space existing in the
India pharmaceutical market.
!nternational Formulations

Alkem Lab's international operations diverge to focus into two distinct business groups Regulated Narkets and Emerging Narkets.
Today, Alkem Lab's has its presence in the USA, Australia and across 40 other countries worldwide.

Alkem Lab's envisions to be a global leader through focus in key markets by setting up of sales and marketing infrastructure and
forging strategic alliances.

Alkem Lab's world class manufacturing facilities are approved by eminent regulatory bodies including US FDA, UK NHRA, TCA
Australia and NCC South Africa amongst several other approvals from emerging markets.

Our worldclass, cCLP compliant RSD infrastructure engage in development of AP! processes and novel forms, generic formulations,
firsttofile opportunities and novel drug delivery systems.

Alkem Lab's has a stateoftheart BA/BE center audited by the US FDA and NHRA UK. Our BA/BE centre supports the formulation
RSD for ANDA, eCTD and other regulatory filings.

Alkem Lab's has an inhouse intellectual property management cell with a team of competent patent attorneys. This team is involved in
safeguarding and securing patent rights for Alkem Lab's products through analysis, strategic planning and indentifying patent
challenging opportunities.

Regulatory affairs is crucial to Alkem Lab's global ambitions and we have ensured that our international operations are supported by
our proficient team of regulatory specialists.

SA
Alkem Lab's seeks to be a successful player in US market and has the necessary infrastructure to achieve this objective. Alkem Lab's
has a dedicated ANDA program and has received approvals for some of its filings while others are pending FDA approval. Alkem Lab's
has forged strategic alliance with a sales and marketing entity to establish itself in the USA. We seek collaborations and alliances in
areas of novel technologies, therapeutic classes and products which will help to accelerate our growth in this region.

%"#AN N!"N
Alkem Lab's has partnered with several companies in Europe for marketing its products. !n key markets like France, Cermany, and the
UK, Alkem Lab's has achieved 'First to Launch' status for some of its products. We have also filed regulatory applications and are on the
anvil of launching several products as part of our expansion plans in the continent.

AST%AL!A
Alkem Lab's has strategic partnership with a reputed generic company which will facilitate the launch of our generic portfolio in
Australia. With several molecules expected to go offpatent in the near future, Australia promises to be a major growth opportunity for
Alkem Lab's.

%C!NC A%TS
Civen the importance of emerging markets and the business potential it holds, Alkem Lab's is taking its portfolio in specific therapeutic
areas viz. antiinfective, cardiovascular, diabetes, gynaecology and CNS to these territories. Alkem Lab's currently has its presence in
markets across specific countries in SouthEast Asia, South America, RussiaC!S and Africa where our branded generics are marketed.

!n some key markets we have our own network of subsidiaries and representative offices. A strong field force supported by country
managers drive our business in these chosen markets.

S"THAST AS!A
SR! LANKA: Alkem Lab's is one amongst the leading pharmaceutical companies in Sri Lanka and has more than 2S brands registered in
the country, including leading brands like TaximO, Zocef and Clavam. Alkem Lab's has a dedicated field force engaged in sales and
marketing of our brands in Srilanka.

TH #H!L!##!NS
Alkem Lab's has established its own subsidiary Alkem Lab's Laboratories Corporation having its office in Nanila and has currently over
S0 regulatory filings in various stages of the approval process. Alkem Lab's products are distributed through Zuellig and has a dedicated
field force engaged in sales and marketing.